Bevacizumab Gamma
A biosimilar version of bevacizumab, the anti-VEGF monoclonal antibody used to treat cancers and neovascular eye diseases. Like the originator product, it inhibits blood vessel growth that tumors or abnormal eye tissue depend on for nutrients. Biosimilars offer comparable efficacy and safety at potentially lower cost.
Area Terapeutik
Mekanisme Kerja
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A biosimilar version of bevacizumab, the anti-VEGF monoclonal antibody used to treat cancers and neovascular eye diseases. Like the originator product, it inhibits blood vessel growth that tumors or abnormal eye tissue depend on for nutrients. Biosimilars offer comparable efficacy and safety at potentially lower cost.
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Yes, Bevacizumab Gamma is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314727. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bevacizumab-gamma"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bevacizumab-gamma/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bevacizumab-gamma/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bevacizumab-gamma/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bevacizumab-gamma"></drugfyi-drug>